What Nexsen does

Nexsen (ASX: NXN) is a clinical-stage nano-biotechnology company founded in 2021 and dual-headquartered in Sydney, Australia (corporate) and Melbourne (R&D at the Royal Melbourne Institute of Technology), with an APAC commercial hub in Hong Kong. The company develops rapid, point-of-care diagnostic sensors built on a proprietary platform that combines ultra-bright nanoparticle chemistry with a modular lateral-flow architecture, enabling multiplexed biomarker detection in minutes at the bedside rather than days in a central laboratory. Its lead product, the GBS Rapid Sensor, targets Group B Streptococcus colonisation in obstetric settings to reduce neonatal sepsis risk, with clinical trials scheduled to commence in Q4 2025. The pipeline reported beyond GBS spans infectious disease, lung cancer, and organ transplant rejection, all served by the same core platform plus an AI-assisted biomarker discovery layer used to screen candidate nano-formulations for diagnostic sensitivity.

The company intends to monetise through device-plus-consumable sales into hospital and clinical laboratory channels, with parallel regulatory pathways pursued in the US (FDA De Novo via regulatory partner MCRA), EU (CE-IVD), and APAC jurisdictions. Distribution and clinical validation are anchored by named partnerships with GHK Hospital, Northern Health, and Universiti Malaya, while R&D capability is supplied by an equity-linked collaboration with RMIT that hosts more than 40 researchers under the direction of Chief Innovation Officer Professor Vipul Bansal. To date, the company has not generated product revenue and is funded primarily through ASX equity issuance and approximately A$11.9 million in cumulative non-dilutive government grants (A$3M Australian, A$1.2M Hong Kong, A$7.7M CRC-P).

Name

Nexsen

Legal name

Nexsen Limited

Website

https://nexsen.bio

Company type

Public

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Nexsen is a clinical-stage nano-biotechnology company developing rapid, point-of-care diagnostic sensors built on proprietary ultra-bright nanoparticle and modular lateral-flow technology, with its lead GBS Rapid Sensor targeting obstetric Group B Streptococcus detection globally.

Ownership category

akta.pro rank

Product category

Point-of-Care Diagnostics

NAICS

Research and Development in Nanotechnology (541713), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Surgical and Medical Instrument Manufacturing (339112)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Biosensors & Lab-on-Chip (BioMEMS) (HDAHALAK)

akta.pro secondary industries

Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

Keywords

• Point-of-care diagnostics
• Nanobiotechnology platform
• Rapid biosensing tests
• Lateral flow diagnostics
• Nanoparticle biomarker sensors

Headquarters

HQ city

Melbourne

HQ country

Australia

HQ region

Oceania

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Diagnostic Device Sales: Nexsen generates revenue through the sale of rapid point-of-care diagnostic devices and sensors. The company is in clinical stage with first product (GBS Rapid Sensor) commencing clinical trials in Q4 2025 and targeting regulatory submissions in CY 2026. Revenue will come from hospital adoption, clinical laboratories, and healthcare providers across human health, agriculture, and biosecurity sectors.
2. Testing/Reagent Sales: Ongoing revenue from consumable test strips and reagents used with the diagnostic platform. The GBS Rapid Sensor uses a vaginal-rectal swab with results visible on a strip similar to pregnancy or COVID tests, implying recurring consumable revenue.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

Core offering

Nexsen develops and sells a modular nano-biotechnology biosensing platform that combines ultra-bright nanoparticles, high-affinity biomarkers, and lateral flow architecture to deliver lab-quality point-of-care diagnostics in a low-cost, paper-based format. The platform powers a multi-product pipeline including the GBS Rapid Sensor (lead product), chronic kidney disease and acute kidney injury tests, a bovine mastitis diagnostic, and biosecurity pathogen tests. First product is in clinical trials (Q4 2025) targeting commercialization in CY 2026.

Product overview

Nexsen is a clinical-stage nano-biotechnology company that has developed a modular biosensing platform combining ultra-bright nanoparticles, high-affinity biomarkers, and modular lateral flow architecture to deliver lab-quality diagnostics in a low-cost, user-friendly format. The platform powers a multi-product pipeline spanning human health, agriculture, and biosecurity. The lead product is the GBS Rapid Sensor (rapid Group B Streptococcus diagnostic), complemented by Chronic Kidney Disease (CKD) and Acute Kidney Injury (AKI) diagnostics in human health, a Bovine Mastitis diagnostic for agriculture, and Biosecurity Pathogen Tests for frontline detection. The platform is developed in partnership with RMIT University's Sir Ian Potter NanoBiosensing Facility and incorporates AI biomarker discovery to accelerate target selection and test performance.

Differentiator

Problem solved

Functional benefit

Products and services

• GBS Rapid Sensor A breakthrough point-of-care rapid diagnostic for Group B Streptococcus using a vaginal-rectal swab that delivers lab-level results in minutes via a pregnancy-test-style strip, targeting the 1 in 4 pregnant women who carry GBS to enable real-time testing at labour.
• Chronic Kidney Disease (CKD) Test A paper-based diagnostic for chronic kidney disease designed for early detection and routine monitoring in clinics, hospitals, and homes, with multi-biomarker capability to identify root causes including diabetes, hypertension, inflammation, and infection.
• Bovine Mastitis Diagnostic A low-cost, field-deployable on-farm test for bovine mastitis that requires no refrigeration and returns results in minutes to reduce losses, improve treatment decisions, and support sustainable dairy operations.

Quantifiable outcome

• GBS affects 1 in 4 pregnant women and is a leading cause of newborn infections
• +4 more outcomes

Named customers2 records

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Partnerships

Six partnerships are on record, tiered core and minor.

• GHK Hospital Limited (Gleneagles Hospital Hong Kong)coreStrategic or Co-development Partner · 12 May 2026Binding term sheet with GHK Hospital Limited, operator of the 500-bed Gleneagles Hospital Hong Kong and part of IHH Healthcare's global network, to clinically validate and commercialize Nexsen's rapid point-of-care diagnostic platform. The collaboration covers clinical validation, real-world data generation, pricing and reimbursement assessments, joint education and training, and creates scope for joint R&D and co-development of new tests targeting Group B Streptococcus and Kidney Function. This partnership reinforces Nexsen's Asia-Pacific strategy and may accelerate its pathway from product development to hospital adoption.
• Universiti MalayacoreStrategic or Co-development Partner · 4 May 2026Formalized partnership to establish a joint research facility for food safety diagnostics at Universiti Malaya's Innovative Medical Devices Centre of Excellence. Under the co-funded agreement, Universiti Malaya contributes 50% of establishment costs, granting Nexsen entry into the Malaysian market alongside existing Hong Kong operations. The facility's first project focuses on developing a rapid dual-sensor biosensor to detect E. coli and Salmonella simultaneously, addressing a critical gap identified by the Malaysian Ministry of Health, with the goal of bringing the product to market within 24 months.
• MCRA (Matrical, LLC)coreImplementation/ SI/ Consulting Partner · 6 November 2025Nexsen partnered with MCRA to accelerate its U.S. market entry for GBS Rapid Sensor and Kidney Function Diagnostics. MCRA will advise on FDA regulatory pathways and market access, with the first FDA interaction expected in early 2026. This partnership supports Nexsen's regulatory strategy for entering the US diagnostics market.
• RMIT University (Sir Ian Potter NanoBiosensing Facility)coreStrategic or Co-development PartnerNexsen's platform was developed at the Sir Ian Potter Nano-Biosensing Facility at RMIT University - Australia's most advanced centre for diagnostics innovation. RMIT's equity partnership in Nexsen marks the first company to receive equity investment from RMIT University - a landmark collaboration between academia and industry. The facility brings together over 40 experts in bio-sensing, nanomaterials, and AI to translate breakthrough science into real-world solutions. Professor Vipul Bansal serves as Chief Innovation Officer and Advisory Board Chair, directing the research facility.
• Northern HealthcoreStrategic or Co-development PartnerNorthern Health is conducting clinical trials for the GBS Rapid Sensor commencing Q4 CY 2025, supported by a $7.7 million CRC-P grant including $3 million in Australian Government funding. Northern Health's Chief Medical Officer, Assoc. Prof. Prahlad Ho, serves on Nexsen's Advisory Board. The trials represent the first commercial product path toward regulatory approval.
• GBS AwareminorGTM or Marketing PartnerNexsen recommends GBS Aware as a trusted resource and advocacy organisation for parents, carers, and clinicians seeking more information about Group B Streptococcus. This represents an educational content partnership to support patient and clinician awareness.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Hologic: Major women's health diagnostics company with established Group B Streptococcus (GBS) testing products. Directly comparable on lead indication (GBS) and broader molecular/rapid diagnostics portfolio serving hospitals and clinical labs globally.
• Atomo Diagnostics: ASX-listed rapid diagnostic platform company developing user-friendly point-of-care test devices. Closely comparable profile: Australian-listed, pre-commercial or early-commercial diagnostics, similar size and stage, with analogous GTM strategy targeting infectious disease and consumer health channels.
• EKF Diagnostics: UK-listed point-of-care diagnostics company producing rapid test devices for clinical and industrial markets including infectious disease, women's health, and animal health. Closely comparable business model and product format to Nexsen's lateral flow platform.
• QuidelOrtho: Specialized rapid diagnostics company with broad lateral flow and immunoassay product lines spanning infectious disease, women's health, and specialty diagnostics. Direct competitor in point-of-care rapid test formats serving similar hospital and clinical channels.

Broad incumbents

• Becton Dickinson (BD): Global medical technology company with BD Veritor rapid diagnostic systems and extensive microbiology/lab diagnostics portfolio. Broad incumbent serving similar hospital and clinical channels with established regulatory and commercial infrastructure.
• Abbott Diagnostics: Global diagnostics leader with extensive rapid diagnostic product lines including Binax and Panbio lateral flow tests, plus point-of-care platforms. Broad incumbent offering overlapping capabilities across all Nexsen target indications as part of a much larger diversified portfolio.
• bioMérieux: Global in vitro diagnostics company with strong microbiology and immunoassay portfolios, including industrial and clinical microbiology testing relevant to Nexsen's biosecurity and food safety applications. Comparable as a broader diagnostics incumbent with relevant overlap on bacterial detection.
• NOW Foods (Animal Health Diagnostics) - IDEXX reference: Global leader in veterinary diagnostics with extensive livestock and dairy testing products including mastitis detection. Relevant comparable for Nexsen's bovine mastitis diagnostic given overlapping customer base (dairy producers, veterinarians) and parallel product format.

Emerging players

• NOWDiagnostics: US-based developer of rapid diagnostic tests including at-home and point-of-care formats using novel detection chemistries. Comparable as an emerging player pursuing decentralized diagnostics with overlapping product strategy in user-friendly rapid test formats.
• Ellume: Australian digital diagnostics company developing connected rapid test platforms for infectious disease. Comparable as a fellow Australian diagnostics innovator with overlapping point-of-care product strategy and similar regulatory pathway challenges.

Market position

Strengths5 records

Weaknesses2 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nexsen